Rush Cancer Center Biorepository Resource

The Rush University Cancer Center Biorepository Resource (RCCB) is a resource within the Rush basic science and clinical trials systems designed to provide key infrastructure to support the accrual of biospecimens from individuals being evaluated or treated for a malignancy at Rush or one of our clinical partner institutions. The strategic accrual, cryopreservation, and assembly of these resources dates back to 2004 and provides investigators with subject cohorts necessary to support specific translational biomedical research studies, as well as streamlining and facilitating collection for new prospective studies and clinical trials. 

Our expansive and strategically-curated biorepository comprises clinical data and matched physical specimens of tissue, processed blood/PBMC products, and collaborative patient-derived organoid (PDO) specimens – our most extensive collections being patient plasma (in excess of 100,000 specimens) and patient serum (in excess of 50,000 specimens) many with time series and/or other matched specimen types available. 

This resource provides investigators and clinicians the opportunity to play lead roles in the innovation of novel preventative, diagnostic and therapeutic approaches that will serve as a foundation by which we offer the latest in individualized therapy to our cancer patients.
 

Leadership